David Henderson, MD
Cardiovascular Disease · Daytona Beach, FLNPI 1750332250
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Abbott at 38.9% of the total. Reporting peaked in 2021 at $36,103 and has fallen 99.0% since, to $362 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 366 payments — averaging $175.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$25K
- Esperion Therapeutics, Inc.$19K
- Johnson & Johnson$11K
- Sanofi-aventis U.S. LLC$6K
- Cvrx, Inc.$418
- Novartis$336
- plus $2K from 29 others
Across 203 payments — averaging $8443.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$898K
- Novartis$384K
- Bayer$113K
- CSL Behring$82K
- AstraZeneca$67K
- Astrazeneca UK Limited$66K
- plus $102K from 5 others
What the payments were for
- Consulting fees$26,39741%
- Speaking & faculty fees$28,20044%
- Travel & lodging$2,2844%
- Food & beverage$7,45712%
- Education$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 75 | $25,068 |
| Esperion Therapeutics, Inc. | 15 | $18,783 |
| Johnson & Johnson | 104 | $11,401 |
| Sanofi-aventis U.S. LLC | 12 | $6,160 |
| Cvrx, Inc. | 22 | $418 |
| Novartis | 27 | $336 |
| Medtronic | 9 | $330 |
| Boehringer Ingelheim | 13 | $242 |
| Amgen | 19 | $242 |
| Atricure, Inc. | 10 | $238 |
| Philips North America LLC | 4 | $157 |
| Pfizer | 9 | $156 |
| Impulse Dynamics (USA) Inc. | 4 | $77 |
| Novo Nordisk | 5 | $74 |
| Kestra Medical Technology Services, Inc. | 3 | $69 |
| Kowa Pharmaceuticals America, Inc. | 5 | $69 |
| E.r. Squibb & Sons, L.L.C. | 5 | $67 |
| Boston Scientific | 3 | $61 |
| Bardy Diagnostics, Inc. | 3 | $48 |
| Opsens Inc. | 1 | $40 |
| Braemar Manufacturing, LLC | 1 | $38 |
| Merck | 2 | $36 |
| United Therapeutics Corporation | 1 | $34 |
| AstraZeneca | 2 | $29 |
| Abiomed | 1 | $28 |
| Acist Medical Systems, Inc. | 1 | $26 |
| Irhythm Technologies, Inc. | 2 | $25 |
| Bayer | 1 | $23 |
| Infobionic, Inc | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Teleflex LLC | 1 | $15 |
| Gilead | 1 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
| Elutia, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXLIZET$18,300
- NEXLETOL$18,300
- Accent Pacemaker$16,680
- XARELTO$10,200
- MULTAQ$5,944
- Confirm Rx$4,595
- AVEIR$2,263
- Tendril Pacing Lead$152
- Quadra Allure MP RF CRT Pacemkr$136
- RESOLUTE ONYX$121
- AMPLATZER AMULET$101
How this compares
$64,380 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 667 | $823,724 |
| XareltoRivaroxaban | 563 | $678,465 |
| EntrestoSacubitril/Valsartan | 237 | $285,545 |
| Repatha SureclickEvolocumab | 172 | $189,699 |
| JardianceEmpagliflozin | 97 | $98,017 |
| FarxigaDapagliflozin Propanediol | 49 | $52,394 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 77 | $24,901 |
| Praluent PenAlirocumab | 35 | $24,739 |
| NexlizetBempedoic Acid/Ezetimibe | 31 | $23,430 |
| Repatha SyringeEvolocumab | 20 | $19,486 |
| Valsartan | 525 | $19,346 |
| NexletolBempedoic Acid | 36 | $19,140 |
| Dofetilide | 41 | $11,840 |
| BrilintaTicagrelor | 15 | $10,647 |
| Ranolazine ErRanolazine | 88 | $10,271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $156 | $823,724667 claims |
| Johnson & JohnsonXarelto | $11,401 | $678,465563 claims |
| NovartisEntresto | $336 | $285,545237 claims |
| Boehringer IngelheimJardiance, Pradaxa | $242 | $103,108116 claims |
| AstraZenecaFarxiga, Brilinta | $29 | $63,04064 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $18,783 | $42,57067 claims |
| Novo NordiskOzempic | $74 | $10,22911 claims |
| AmgenCorlanor | $242 | $6,44911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Daytona Beach
- Dinesh ArabDaytona Beach$107K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.